WHO ICTRP trial
A prospective randomized controlled trial on the treatment of locally advanced…
ChiCTR2000040444 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000040444 |
|---|---|
| Public title | A prospective randomized controlled trial on the treatment of locally advanced esophageal squamous cell carcinoma with anlotinib combined with simultaneous radiotherapy and chemotherapy |
| Scientific title | A prospective randomized controlled trial on the treatment of locally advanced esophageal squamous cell carcinoma with anlotinib combined with simultaneous radiotherapy and chemotherapy |
| Primary sponsor | Shandong Tumor Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | esophageal squamous cell carcinoma |
| Interventions | experimental group:anlotinib combined with simultaneous radiotherapy and chemotherapy;controlled group:simultaneous radiotherapy and chemotherapy |
| Registration date | Nov 28, 2020 |
| Target size | experimental group:50;controlled group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: